Skaistė Žukaitienė

Mrs. Skaistė Žukaitienė

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2018 in Medicina
Verified
Journal Article
Open access
PDF file
SŽSkaistė Žukaitienė
Skaistė Žukaitienė
GGGintautas Gumbrevicius
Gintautas Gumbrevicius
AVAušra Vendzelytė
Aušra Vendzelytė
ASArunas Sciupokas
Arunas Sciupokas
KPKęstutis Petrikonis
Kęstutis Petrikonis
EKEdmundas Kaduševičius
Edmundas Kaduševičius
Background and objective: Irrational use of nonsteroidal anti-inflammatory drugs (NSAIDs) is the main cause of adverse effects-associated hospitalizations among all medication groups leading to extremely increased costs for health care. Pharmacoepidemiological studies can partly reveal such issues and encourage further decisions. Therefore, the aim of our study was to evaluate the utilization of non-opioid analgesics (ATC classification N02B and M01A) in Lithuania, and to compare it with that of other Baltic and Scandinavian countries in terms of compliance to the WHO pain treatment guidelines and the EMA safety recommendations on NSAID use. Materials and methods: The dispensing data were obtained from the sales analysis software provider in the Baltic countries (SoftDent, Ltd., Kaunas, Lithuania); State Medicine Control Agencies of Lithuania, Latvia, and Estonia; Norwegian Prescription Database; Swedish Database for Medicines; and Danish Prescription Database. Data included the utilization of both prescription and over-the-counter drugs. Utilization was expressed in defined daily doses (DDD)/1000 inhabitants/day. Results: During the 11-year period, the utilization of drugs belonging to the N02B and M01A groups increased by 22.8%, from 58.37 in 2005 to 71.68 DDD/1000 inhabitants/day in 2016 in Lithuania. Contrary to the WHO guidelines on pain management, all Baltic countries were more likely to use NSAIDs than other analgesics and antipyretics: in 2015, the drugs of the M01A group were used 6.04, 5.79, and 6.11 times more than those of N02B in Lithuania, Estonia, and Latvia, respectively, whereas the Scandinavian countries preferred the N02B to the M01A group: in Denmark and Sweden, the utilization of other analgesics and antipyretics was 2.33 and 1.24, respectively, times higher than that of NSAIDs. In Norway, the use of both groups was similar. In the Scandinavian countries, paracetamol was the analgesic of first choice, whereas, in Lithuania, it took only the third place. The most popular drug in Lithuania was diclofenac, and its utilization accounted for 30.04% of all non-opioid analgesics in 2016. Although the European Medicines Agency (EMA) restricted the use of certain NSAIDs, i.e., cyclooxygenase-2 (COX-2) inhibitors, nimesulide, and diclofenac, their use consistently increased by 15.91, 2.83, and 1.41 times, respectively, showing incompliance with the international guidelines. Conclusions: Neither the EMA safety policy on NSAID use nor the WHO pain treatment guidelines had a sufficient impact on the rational use of NSAIDs in Lithuania. The use of NSAIDs restricted by the EMA (diclofenac, COX-2 inhibitors, nimesulide, and piroxicam) remains high or even increases, while the utilization of safer alternatives (paracetamol and naproxen) remains relatively low as compared with the Scandinavian countries. Incompliance with international guidelines may result in increased morbidity, mortality and higher costs for health care.

5 November 2025 in Medicina
Verified
Journal Article
Open access
PDF file
SŽSkaistė Žukaitienė
Skaistė Žukaitienė
KBKarolis Bareikis
Karolis Bareikis
SSSimona Stankeviciute
Simona Stankeviciute
AUAkvile Usaite
Akvile Usaite
NBNeringa Balčiūnienė
Neringa Balčiūnienė
RMRomaldas Mačiulaitis
Romaldas Mačiulaitis
Background and Objectives: Post-surgical central nervous system (CNS) infections are severe complications associated with high morbidity and mortality. Vancomycin is a key antibiotic used in their management. However, because of the restrictive properties of the blood–brain barrier (BBB), plasma concentrations may not accurately reflect drug exposure in the brain extracellular fluid (ECF), the presumed site of infection. Cerebral microdialysis enables direct measurement of unbound drug levels in brain ECF. This study aimed to assess vancomycin penetration into brain ECF in patients with suspected or confirmed post-surgical CNS infection. Materials and Methods: Five patients with suspected or confirmed post-surgical CNS infections were enrolled. Paired brain ECF microdialysate and plasma samples (and cerebrospinal fluid (CSF) samples, when available) were collected over two consecutive days at vancomycin steady state. Vancomycin concentrations were determined using a homogeneous enzyme immunoassay and corrected for probe recovery based on in vitro calibration. Pharmacokinetic parameters, including mean concentrations and 24-h area under the concentration–time curve (AUC24), were calculated for plasma and ECF, and ECF-to-plasma ratios were derived. Results: Two subgroups could be identified: patients with negligible ECF concentrations (“low penetrators”), and those with higher ECF levels (“high penetrators”). Mean (SD) ECF-to-plasma concentration ratios were 0.07 (0.04) in “low penetrators” and 0.44 (0.10) in “high penetrators”. The corresponding AUC24 ratios were 0.06 (0.03) and 0.40 (0.03), respectively. The presence of systemic inflammatory response syndrome (SIRS) was considered the most plausible factor differentiating these two subgroups. Conclusions: Vancomycin exposure in brain ECF demonstrated substantial interpatient variability in post-surgical CNS infections, with some patients showing minimal drug penetration.

14 October 2025 in Pharmacology Research & Perspectives
Verified
Journal Article
Open access
SŽSkaistė Žukaitienė
Skaistė Žukaitienė
AŽAinė Žygaitė
Ainė Žygaitė
GMGabrielė Milkintaitė
Gabrielė Milkintaitė
JPJolita Pancerė
Jolita Pancerė
NBNeringa Balčiūnienė
Neringa Balčiūnienė
RMRomaldas Mačiulaitis
Romaldas Mačiulaitis
Postoperative central nervous system (CNS) infections are associated with high mortality and present a therapeutic challenge due to limited antibiotic penetration into the brain extracellular fluid (ECF). Vancomycin, frequently used in this setting, requires therapeutic drug monitoring; however, its quantification in brain ECF via microdialysis is limited by the need for accurate calibration of relative recovery (RR). This study aimed to determine the in vitro RR of vancomycin under conditions simulating clinical neuromonitoring to support application in clinical practice. Vancomycin RR was assessed using forward dialysis and retrodialysis techniques at a fixed perfusion rate of 0.3 μL/min, consistent with standard neuromonitoring protocols. Vancomycin concentrations were measured using a homogeneous enzyme immunoassay across subtherapeutic, therapeutic, and supratherapeutic levels. RR was calculated as the ratio of microdialysate to reference solution concentrations. Mean RR was 86.5% (SD 3.6%) for forward dialysis and 86.4% (SD 2.1%) for retrodialysis, with no significant difference between techniques (p = 0.957). RR remained consistent across all tested concentration levels (p = 0.051). A strong correlation was observed between vancomycin concentrations in the microdialysate and the study solution (r = 0.997, p < 0.001). The high and stable RR achieved under clinically relevant conditions supports the use of this in vitro microdialysis model as a reliable calibration tool. This model may aid in estimating vancomycin concentrations in brain fluid, facilitating dose optimization in patients undergoing microdialysis‐based monitoring for postoperative CNS infections.

23 July 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
JBJogaile Butauskaite
Jogaile Butauskaite
AZAusteja Zumbakyte
Austeja Zumbakyte
LALauryna Aukstikalne
Lauryna Aukstikalne
JPJolita Pancere
Jolita Pancere
SŽSkaistė Žukaitienė
Skaistė Žukaitienė
EKEgle Karinauske
Egle Karinauske
With increasing numbers of older adults worldwide, multimorbidity and polypharmacy are on the rise, highlighting the risks of harmful drug-drug interactions (DDIs) to patients. As cardiovascular agents are among the most prescribed medications, we performed an observational cross-sectional study to determine the prevalence of DDIs in a cardiology department of a secondary hospital. Patient data was obtained from medical records and screened for DDIs using the Micromedex drug interaction software. Descriptive statistics, Chi-square (χ2) test, Student's t test and Pearson's correlation test were used to analyse the results. Out of 50 participants, 45 (90%) had at least one DDI. A total of 266 DDIs were identified, with more than half classified as major. At least one major DDI was found in 78% of patients. 42% of patients were at an increased risk of bleeding due to DDIs. A statistically significant relationship was found between the detection of DDIs and both patient age (p = 0.005) and the number of drugs used (p < 0.001). Our findings pose questions about the wider prevalence and risks of drug-drug interactions among patients with cardiovascular disease.

21 October 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
SŽSkaistė Žukaitienė
Skaistė Žukaitienė
KBKarolis Bareikis
Karolis Bareikis
SSSimona Stankevičiūtė
Simona Stankevičiūtė
AŪAkvilė Ūsaitė
Akvilė Ūsaitė
JPJolita Pancerė
Jolita Pancerė
RMRomaldas Mačiulaitis
Romaldas Mačiulaitis
Background/Objectives: Postoperative central nervous system (CNS) infections are severe compli-cations of neurosurgery, and vancomycin is a cornerstone of empirical and targeted therapy; how-ever, longitudinal vancomycin exposure in this population is poorly characterized. Methods: We conducted a single-centre retrospective cohort study of 189 postoperative CNS infection episodes in 174 adults treated between 2020 and 2026, focusing on longitudinal vancomycin exposure and pharmacokinetic.pharmacodynamic (PK/PD) target attainment according to therapeutic drug mon-itoring (TDM) status. A population pharmacokinetic (PopPK) model, developed from 193 concen-trations was used to reconstruct exposure in TDM episodes and simulate exposure for no TDM ep-isodes. Results: The final PopPK model confirmed creatinine clearance (CrCl) as the principal de-terminant of vancomycin clearance; higher baseline CrCl independently predicted a greater propor-tion of treatment time with AUC24 <400 mg·h/L. Underexposure occurred throughout: patients spent 37.2% (TDM) and 47.5% (no TDM) of evaluable treatment time below AUC24 400 mg·h/L, with early underexposure even more common in both groups. The TDM group spent more time within the AUC₂₄ 400–600 mg·h/L range (43.23% vs 29.91%). No statistically significant exposure–outcome associations were identified in the overall population. In an exploratory ICU subgroup analysis, higher mean AUC₂₄ was associated with clinical improvement within 72 h (OR 1.92 per 100 mg·h/L increase, 95% CI 1.12–3.28), although the exposure-by-ICU interaction was not statistically signifi-cant. Conclusions: These findings support early and repeated vancomycin TDM throughout treat-ment to identify and address underexposure, particularly in patients with augmented renal function and those treated in ICU.